Nutraceutical M&As: How strategic mergers are shaping the health and wellness market
Express Pharma|December 2024
The nutraceutical industry has seen a surge in M&A activity over the past three years as companies pursue strategic acquisitions to strengthen market positions, diversify offerings, and drive innovation. Sudhindran N, GM - Corporate Affairs, Nutrify Today explores key trends, motivations, notable deals, and future growth prospects shaping the industry
Nutraceutical M&As: How strategic mergers are shaping the health and wellness market

The nutraceutical industry-where nutrition meets pharmaceuticals has been a hotbed for mergers and acquisitions (M&A) over the past three years, with a wave of deals driven by consumer demand, the quest for innovation, and the push for global expansion. As health and wellness trends become more pronounced, major players are betting big on M&A to consolidate their market positions, diversify their portfolios, and stay ahead in an increasingly competitive landscape. Here's a closer look at the key M&A trends, motivations, notable deals, and future prospects shaping the nutra industry.

Key trends in nutra M&A

◆ Surge in deal volume and value: From 2021 to 2023, nutra M&A activity saw a major uptick in both deal volume and value. The global nutra market surpassed $423 billion in 2022 and is forecasted to expand at a 4.5 per cent CAGR through 2032, as per Global Market Insights. The uptrend reflects heightened consumer awareness around health, with companies vying to strengthen their market positions through strategic acquisitions.

◆ Rising cross-border transactions: Cross-border deals have surged as companies from developed markets like the US and Europe acquire firms in emerging markets such as Asia-Pacific and Latin America. With rapid consumer growth in these regions, this approach helps companies tap into new markets and secure higher growth potential. For instance, Nestlé Health Science's acquisition of Atrium Innovations in 2018 set a strategic precedent for cross-border acquisitions in the nutra sector.

This story is from the December 2024 edition of Express Pharma.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

This story is from the December 2024 edition of Express Pharma.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

MORE STORIES FROM EXPRESS PHARMAView All
CILICANT is changing the way we think about active packaging
Express Pharma

CILICANT is changing the way we think about active packaging

Team CILICANT shared insights into their journey of innovation, customer-centric solutions, and their ambitious plans for global expansion. In this engaging dialogue, the team also shed light on their unique value proposition, recent achievements, and strategies for adapting to a rapidly evolving pharma landscape, in an exclusive conversation with Express Pharma

time-read
4 mins  |
January 2025
KPMG 2024 Life Sciences CEO Outlook
Express Pharma

KPMG 2024 Life Sciences CEO Outlook

This recent KPMG report explores the perspectives and priorities of life sciences CEOs amid economic and geopolitical uncertainty, focusing on growth strategies, digital transformation, ESG goals, and workforce challenges. Excerpts from the report

time-read
7 mins  |
January 2025
Nutraceuticals 2025: Mapping growth, innovation, and consumer-centric trends
Express Pharma

Nutraceuticals 2025: Mapping growth, innovation, and consumer-centric trends

Industry experts highlight the evolving dynamics, regulatory needs, and personalised solutions driving the nutra market ahead of 2025

time-read
4 mins  |
January 2025
We aim to strengthen our presence in Asian and MENA regions, with particular emphasis on India
Express Pharma

We aim to strengthen our presence in Asian and MENA regions, with particular emphasis on India

Matthias Poslovski, Chief Sales Officer, Optima Pharma, speaks on the company's evolution and shares insights on emerging trends like personalised medicine, digitalisation, and Al-driven technologies, while outlining his company's strategies for market expansion, particularly in Asia and MENA, with a focus on the Indian pharma sector, in an exclusive interaction with Lakshmipriya Nair

time-read
4 mins  |
January 2025
Sustaining excellence: The evolving role of quality in pharma
Express Pharma

Sustaining excellence: The evolving role of quality in pharma

In the ever-evolving landscape of the pharma industry, the pursuit of quality remains a cornerstone of success. As stringent regulatory frameworks, rising patient expectations, and the increasing pace of innovation, transforms the pharma industry, the definition of quality is also evolving. From ensuring compliance with global standards to embracing cutting-edge technologies like Al-driven quality control, the industry is navigating a paradigm shift in how it approaches product integrity, safety, and efficacy. In this New Year issue, pharma experts explore how crucial it is to foster a culture of quality across organisations and deliver better healthcare outcomes

time-read
5 mins  |
January 2025
Revolutionising pharma the adaptive way
Express Pharma

Revolutionising pharma the adaptive way

Adaptive manufacturing offers better performance, efficient management of diverse products, a reduced machine footprint, faster batch changes, and enhanced operational sustainability

time-read
3 mins  |
January 2025
Trends 2025: Redefining the pharma supply chain
Express Pharma

Trends 2025: Redefining the pharma supply chain

Saurabh Gupta, Global Head of Supply Chain, Lupin highlights trends such as Al integration, digitalisation and sustainability that are shaping a future-ready supply chain

time-read
4 mins  |
January 2025
Growth mantras for 2025: Innovation, Partnerships, Sustainability
Express Pharma

Growth mantras for 2025: Innovation, Partnerships, Sustainability

Innovation, synergy, and sustainability are shaping the trajectory of India's pharma sector, unlocking new frontiers of growth, inform industry stakeholders

time-read
2 mins  |
January 2025
Will Epygen's biosimilars bets pay off?
Express Pharma

Will Epygen's biosimilars bets pay off?

Debayan Ghosh, founder, Epygen Group, has ambitious plans to snag a slice of the booming $70 billion global biosimilar pie. In a conversation with Viveka Roychowdhury, he analyses the journey so far, spanning pandemic preparedness projects like protein-based vaccines, building up pipeline revenue streams in diabetes, oncology, immunology and cardiovascular biosimilars, and his strategies to scale up and expand to other therapeutics like anti-obesity drugs

time-read
9 mins  |
January 2025
Innovation, partnerships and best practices: Priorities for biopharma in 2025
Express Pharma

Innovation, partnerships and best practices: Priorities for biopharma in 2025

Industry experts highlight the progress made by the Indian biopharma sector, and suggest pathways to promote growth

time-read
3 mins  |
January 2025